ImageneBio (NASDAQ:IMA) Releases Quarterly Earnings Results, Beats Estimates By $0.27 EPS

ImageneBio (NASDAQ:IMA) announced its earnings results on Wednesday. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.27, FiscalAI reports.

ImageneBio Price Performance

NASDAQ:IMA traded down $0.39 on Thursday, hitting $5.36. 10,975 shares of the company’s stock were exchanged, compared to its average volume of 161,122. The company has a market cap of $57.12 million, a P/E ratio of -0.93 and a beta of 0.76. The firm has a 50-day moving average price of $5.77 and a 200-day moving average price of $5.97. ImageneBio has a 52 week low of $3.94 and a 52 week high of $15.79.

Analyst Ratings Changes

IMA has been the topic of a number of analyst reports. Wall Street Zen lowered shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. Wedbush restated an “underperform” rating on shares of ImageneBio in a research note on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of ImageneBio in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $30.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Rangeley Capital LLC boosted its position in shares of ImageneBio by 78.6% in the first quarter. Rangeley Capital LLC now owns 32,590 shares of the company’s stock valued at $163,000 after acquiring an additional 14,346 shares during the period. Renaissance Technologies LLC grew its position in shares of ImageneBio by 23.6% during the 1st quarter. Renaissance Technologies LLC now owns 81,696 shares of the company’s stock worth $408,000 after purchasing an additional 15,600 shares in the last quarter. BML Capital Management LLC increased its holdings in shares of ImageneBio by 13.4% during the first quarter. BML Capital Management LLC now owns 200,730 shares of the company’s stock worth $1,004,000 after purchasing an additional 23,704 shares during the period. Hsbc Holdings PLC bought a new position in shares of ImageneBio during the fourth quarter worth approximately $233,000. Finally, Millennium Management LLC acquired a new stake in shares of ImageneBio in the fourth quarter valued at approximately $79,000. Institutional investors own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.